Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV001781144 | SCV002025203 | likely pathogenic | not provided | 2020-07-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001885183 | SCV002142406 | pathogenic | Glycogen storage disease, type II | 2021-11-26 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GAA protein function. For these reasons, this variant has been classified as Pathogenic. This missense change has been observed in individual(s) with Pompe disease (PMID: 15986226, 32711049). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces histidine, which is basic and polar, with leucine, which is neutral and non-polar, at codon 568 of the GAA protein (p.His568Leu). |
Baylor Genetics | RCV001885183 | SCV004195459 | pathogenic | Glycogen storage disease, type II | 2023-10-03 | criteria provided, single submitter | clinical testing |